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Simple Summary: Multigene testing in ovarian cancer has received increased support due to its‘
applicability for cancer treatment and the impact it has on cancer prevention in families. This study
shows that multi-gene germline and somatic testing uptake after counselling by a member of the
multidisciplinary cancer clinical team in women with ovarian cancer, was high (97%). A total of 15.5%
of women were identified to have germline BRCA1/BRCA2 pathogenic variants and 7.8% had somatic
BRCA1/BRCA2 pathogenic variants. A total of 2.3% patients had RAD51C/RAD51D/BRIP1 pathogenic
variants. We found that 11% of germline pathogenic variants were large-genomic-rearrangements
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and were missed by somatic testing. Our findings support prospective parallel somatic-&-germline
panel testing to maximize variant identification.
Abstract: We present findings of a cancer multidisciplinary-team (MDT) coordinated mainstream-
ing pathway of unselected 5-panel germline BRCA1/BRCA2/RAD51C/RAD51D/BRIP1 and parallel
somatic BRCA1/BRCA2 testing in all women with epithelial-OC and highlight the discordance be-
tween germline and somatic testing strategies across two cancer centres. Patients were counselled
and consented by a cancer MDT member. The uptake of parallel multi-gene germline and somatic
testing was 97.7%. Counselling by clinical-nurse-specialist more frequently needed >1 consulta-
tion (53.6% (30/56)) compared to a medical (15.0% (21/137)) or surgical oncologist (15.3% (17/110))
(p < 0.001). The median age was 54 (IQR = 51–62) years in germline pathogenic-variant (PV) versus
61 (IQR = 51–71) in BRCA wild-type (p = 0.001). There was no significant difference in distribution of
PVs by ethnicity, stage, surgery timing or resection status. A total of 15.5% germline and 7.8% somatic
BRCA1/BRCA2 PVs were identified. A total of 2.3% patients had RAD51C/RAD51D/BRIP1 PVs. A
total of 11% germline PVs were large-genomic-rearrangements and missed by somatic testing. A
total of 20% germline PVs are missed by somatic first BRCA-testing approach and 55.6% germline
PVs missed by family history ascertainment. The somatic testing failure rate is higher (23%) for
patients undergoing diagnostic biopsies. Our findings favour a prospective parallel somatic and
germline panel testing approach as a clinically efficient strategy to maximise variant identification.
UK Genomics test-directory criteria should be expanded to include a panel of OC genes.
Keywords: ovarian cancer; BRCA; genetic testing; germline; somatic; RAD51C; RAD51D; BRIP1
1. Introduction
Ovarian cancer (OC) is the leading cause of deaths from gynaecological cancers, with
240,000 new cases and 152,000 deaths occurring worldwide annually [1]. GLOBOCAN data
suggest the number of cases from OC will increase by 26% in the UK and 47% worldwide,
respectively, over the next 20 years [1]. Standard treatment approaches have been associated
with limited long-term OC survival of ~30% [2]. However, the progress over the last
10–15 years has provided the foundations for a precision medicine [3] approach for OC
management, involving inherited cancer susceptibility genes. BRCA1/BRCA2 pathogenic
and likely pathogenic variants (henceforth termed ‘pathogenic variants’ or ‘PVs’) account
for most of the known inheritable risk of OC. Around 11–18% of OC have germline
BRCA1/BRCA2 PV and another 6–9% have a somatic BRCA1/BRCA2 PV in the tumour
tissue alone which is not inherited. Women with germline BRCA1/BRCA2 PVs have a
cumulative risk by age 80 of 17–44% for developing EOC and 69–72% for developing breast
cancer (BC) [4].
Genetic testing for OC susceptibility genes has recently received an impetus through
increasing applicability for cancer treatment and eligibility for clinical trials. The proteins
coded by BRCA1/BRCA2 are essential in the homologous recombination repair (HRR) of
double stranded DNA breaks, whilst PARP (poly ADP ribose polymerase) is an essen-
tial component of single-strand DNA repair. Inhibition of PARP increases double strand
breaks and prevents HRR deficient (HRD) tumour cells from surviving chemotherapy
induced DNA damage, leading to synthetic lethality [5]. Germline as well as somatic BRCA
mutated OC have been shown to benefit from ‘PARP inhibitor’ (PARP-i) therapy with im-
proved progression free survival at both recurrent and more recently primary settings [5–9].
Therefore, knowledge of BRCA status at the time of diagnosis has become pivotal in the
guidance of treatment options. Genetic testing for germline BRCA1/BRCA2 PVs in EOC
was commissioned by NHS-England in 2015 [10], and has been recommended by other
published guidelines over the last few years [11]. More recently, the American Society of
Clinical Oncology (ASCO) [12], the British Gynaecological Cancer Society (BGCS) [13] and
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the European Society of Medical Oncology (ESMO) [14] have advocated for somatic testing
too.
However, HRD can arise through somatic and germline PV in a wide range of OC
susceptibility genes [15]. Approximately 50% of high-grade serous OC are characterised
by HRD suggesting additional mechanisms other than BRCA mutations play a significant
role [14]. HRD assays are now available and are beginning to be used in clinical practice [14].
Further moderate risk OC susceptibility genes in the HRR pathway, such as, RAD51C,
RAD51D and BRIP1 with lifetime OC-risks of 5.8 to 13% have been identified and their
risks validated [16,17]. Testing for additional genes of clinical utility [18] can lead to
wider therapeutic benefit. ASCO now recommends germline BRCA testing within the
context of a multigene panel [12]. In addition to targeted therapy, identification of PVs
offers opportunities for cancer surveillance and prevention for secondary cancers in index
patients as well as cascade testing in relatives. Unaffected relatives with PVs can access
relevant surgical prevention and screening options which have well established clinical
benefit. This includes risk-reducing salpingo-oophorectomy (RRSO) to reduce their OC
risk [19,20]; MRI/mammography screening, or risk reducing mastectomy (RRM) [21], or
chemoprevention with selective oestrogen receptor modulators (SERM) to reduce their BC
risk [22].
Over recent years, many models of care delivery for OC genetic testing have been
implemented into clinical practice [23–25]. There has been great variation in these clinical
pathways, with strategies varying with respect to (a) whom to test (unselected or restricted
by histology such as for high-grade serous OC or restricted by age, such as under 70 years);
(b) what to test (either germline only, or somatic only, or both) and (c) in which order to test
(parallel or sequential); (d) which genes to test (BRCA only or multiple genes); and (e) who
provides counselling and testing (genetics teams in genetics clinics, genetics professional
embedded in oncology clinics, medical oncologists, surgical oncologists, or clinical nurse
specialists (CNS)). Despite guidelines, historically, the overall uptake and access to genetic
testing across health systems has remained poor, with only 20–30% eligible patients access-
ing testing [26,27]. Obstacles to introducing routine somatic testing at diagnosis have been
attributed to reasons like cost, access/availability of validated somatic testing in a National
Health Service (NHS) accredited laboratory and additional resources required to process
tumour samples [28]. Most studies to date report clinical experience of implementing BRCA
testing. Reports of systematic prospective parallel germline panel and somatic genetic
testing are limited. We present our experience and findings of implementing a cancer
multidisciplinary team (MDT) coordinated mainstreaming pathway of unselected 5-panel
germline BRCA1, BRCA2, RAD51C, RAD51D, BRIP1 and parallel somatic BRCA1/BRCA2
testing in all women with high grade non-mucinous epithelial OC in the Systematic Genetic
Testing for Personalised Ovarian Cancer Therapy (SIGNPOST) study (ISRCTN: 16988857)
in women from North East London Cancer Network (NELCN). We report on the somatic
testing success rates with different types of sample ascertainment. Moreover, importantly
we highlight the discordance between germline and somatic testing strategies incorporating
testing data from NELCN as well as the Manchester NHS Foundation trust.
2. Materials and Methods
2.1. Pre-Test Counselling and Recruitment
Women ≥18 years with high-grade non-mucinous epithelial OC, who were newly
diagnosed or under follow-up in the NELCN, were offered parallel germline testing
for BRCA1, BRCA2, RAD51C, RAD51D, BRIP1 genes and concomitant BRCA1/BRCA2
somatic genetic testing. This was undertaken through the SIGNPOST study (ISRCTN:
16988857). Newly diagnosed patients were identified from gynaecological oncology MDT
meetings and consented for genetic testing during their primary treatment. Patients
undergoing surveillance post-treatment, were identified through follow-up surgical and
medical oncology clinics as well as pathology and clinical databases. Eligibility for genetic
testing was established by the treating clinician. Patients received written pre-test education
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information regarding the advantages, disadvantages and implications of genetic-testing.
Pre-test genetic counselling and consent was undertaken at routine clinic visits. This
was led initially by medical and surgical oncology consultants, and subsequently also
undertaken by cancer CNSs. Psychological support was offered by CNSs within the cancer
services.
2.2. Germline and Somatic Testing
Testing was undertaken by clinically accredited NHS laboratories. A 4 mL EDTA blood
sample was taken for germline genetic testing for BRCA1, BRCA2, RAD51C, RAD51D and
BRIP1. Germline testing for NELCN samples was undertaken for BRCA1, BRCA2, RAD51C,
RAD51D and BRIP1 at the North East Thames Regional Genomics Laboratory (Great Or-
mond Street Hospital), while for Manchester samples testing for BRCA1 and BRCA2 was
undertaken at the Genomic Diagnostic Laboratory at the North West Genomic Laboratory
Hub. This was carried out using next generation sequencing (NGS; Agilent SureSelect and
Illumina NextSeq) of the coding region, sequenced to a minimum depth of 30 reads, in-
cluding intron/exon splice boundaries. Sanger sequencing was also carried out to confirm
variants detected during the NGS screen. Additionally, exon deletions/duplications in
BRCA1 and BRCA2 genes were detected using Exome Depth. Multiplex ligation-dependent
probe amplification (MLPA; MRC Holland) kits P002-D1 and P090-C1, respectively.
Somatic testing was undertaken using formalin fixed paraffin embedded (FFPE)
tissue specimen from diagnostic biopsies, or up front cytoreductive surgery or post-
chemotherapy cytoreductive surgery as appropriate. FFPE blocks were reviewed by a
consultant histopathologist to identify areas with >20% tumour content and therefore
deemed suitable for somatic testing. The specimens were processed and sent as either
5 × 5 µM thick unstained sections, or as 3 mm core biopsies from paraffin blocks. Un-
stained slides were preferred for small volume diagnostic biopsies and in <20% neoplastic
content. Tumour blocks were selected by the pathologist and graded as <20%, 20–50%
and >50% neoplastic content. Testing was undertaken in two NHS accredited diagnostic
laboratories. Majority NELCN and Manchester samples were analysed at the Manchester
Genomics Laboratory while a few NELCN samples were also tested at the Royal Marsden
Hospital laboratory. Detection of variants is dependent on the percentage of tumour infil-
tration, DNA input concentration and DNA quality. DNA extracted from FFPE tissue was
analysed in the coding regions of BRCA1 and BRCA2, using NGS and minimum variant
allele depth was 10×. The analysis was performed with Molecular Diagnostics Information
Management System v-4.0, based on genome hg19 or GeneRead DNAseq v2 Human Breast
Cancer Panel (Qiagen) and Illumina NGS. Mutation and variant calling by custom bioinfor-
matic analysis pipeline validated to detect SNVs and small insertion/deletion mutations
(<40 bp) to 5% mutant allele frequency (MAF).
Variants were classified using the ACGS and CanVIG guidance in force (https://
www.acgs.uk.com/quality/best-practice-guidelines/ (accessed on 5 January 2021)) [29,30].
Common, high frequency benign and likely benign variants were filtered bioinformatically
from a curated list of variants whilst all other variants were assessed by a registered
Clinical Scientist. In case of discordance between the germline and somatic samples, a
further repeat analysis was undertaken and second report issued. Reports from both
germline and somatic tests were sent to the referring clinician for disclosure to the patients.
Validation of 3 mm FFPE punch biopsies for high-volume somatic testing:
Somatic testing using NGS on FFPE specimens has been validated on 5 × 5 µM thick
unstained sections. [31] In order to minimise delay without compromising DNA yield,
particularly for archival FFPE tissue, 3 mm punch biopsies from FFPE tumour blocks
were validated for diagnostic somatic testing. Following review by a gynaecological
oncology histopathologist, a 5 mm area with high tumour content (>20%) was marked on
the Haematoxylin and Eosin (H&E) stain slide. Keyes punch biopsy (routinely used for
skin biopsy) was used to core out 3 mm sample from corresponding area in FFPE block.
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Five 5 µM thick unstained sections were also cut from same block. Five matched 3 mm
cores and unstained sections were compared for DNA yield.
2.3. Test Result Management
Most patients including all those diagnosed with a PV were given their test result and
counselled in an outpatient clinic by their consenting and treating cancer clinician. A small
proportion of patients on long-term follow up declined an additional hospital visit and
were given the result by post. All patients with a PV were referred to North East Thames
regional genetics service team for additional post-test genetic counselling and facilitating
predictive testing in family members.
We report on testing undertaken between 01/05/2017 to 31/12/2019 across the
NELCN, which provides cancer care to a ~1.7 M population covering six NHS hospi-
tals. Patient demographic and clinical data were extracted from electronic patient records,
and FH questionnaires completed by the patient. Positive (or strong) FH was defined as
any index case of high-grade non-mucinous epithelial OC and breast cancer or epithelial
OC in a first-degree or second-degree relative. Patients who had previously undergone
genetic testing as they had been referred to clinical genetics in view of a strong FH, were
excluded from mainstreaming, but are included in the analysis of prevalence estimates.
For the analysis of discordance between germline and somatic BRCA1/BRCA2 testing we
also include data of 116 unselected OC cases from Manchester NHS Foundation trust
who underwent parallel germline and somatic testing. The testing procedures and offer
of testing was similarly undertaken in Manchester but germline testing was restricted to
BRCA1 and BRCA2.
Descriptive statistics were used for baseline characteristics. PV and wild type groups
were compared for ethnicity, age, FH, histology, stage, timing of surgery, chemotherapy
response score, and residual disease status. Variables associated with number of pre-test
consultations (1 or >1) were explored for type of clinician undertaking counselling, disease
status at time of counselling (new diagnosis or on follow up) and treatment status (whether
undergoing active treatment or not).
Wilcoxon rank-sum test and Fisher’s exact or Chi-square tests were used to test the
difference in means and proportions correspondingly. Two-sided p-values were reported




Development of the genetic testing pathway was preceded by a wide consultation
with the regional clinical geneticists, genetic counsellors, surgical and medical oncologists,
CNS, clinical scientists from genetic laboratories, patient representatives and BRCA charity
leads. Patient representatives and charity leads expressed a preference for genetic testing
to be provided at diagnosis, to be made available all patients including those remained
under surveillance post-treatment, and for provision for adequate pre-test counselling and
informed consent.
In preparation of a cancer MDT coordinated mainstreaming genetic testing service, all
gynaecological cancer MDT members (surgical oncologists, medical oncologist, patholo-
gist and CNS) attended small group teaching sessions led by the regional lead in clinical
genetics and a gynaecological oncologist with a long-standing special interest and signif-
icant experience in cancer genetics, counselling and testing. This covered principles of
Mendelian inheritance, OC susceptibility genes and associated cancer risks; the principles,
structure and factors specific to genetic counselling; as well as the developed local testing
and referral pathways. Knowledge questionnaires were completed by attendees to ensure
appropriate understanding of issues. Following pathway implementation, ongoing profes-
sional support for the cancer MDT team was provided by gynaecological cancer precision
prevention service, with support from the regional clinical genetics team. Pre-counselling
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written information was developed in collaboration with the major stakeholders and pro-
vided to all patients. Additionally, service management meetings across the broader group
with representation from medical and surgical oncologist, lead clinical geneticist, clinical
scientists from genetic laboratories, lead histopathologist were held every 6–9 months.
Counselling, Recruitment and Genetic Testing:
A total of 310 patients with high-grade non-mucinous epithelial OC who were eligible
for genetic testing were identified across the NELCN. This included 188 newly diagnosed
women and 122 patients on follow up post-treatment. Of these women seven were excluded:
four died prior to commencing treatment, one was unable to consent due to dementia
and learning difficulties and two declined genetic testing. The remainder 303 untested
patients remained eligible for testing and received pre-test genetic counselling. Of these
patients 7/122 (6%) under surveillance had previously undergone germline BRCA1/BRCA2
mutation testing through clinical genetics due to a strong FH of BC or OC fulfilling prior
standard clinical criteria for genetic testing. They were offered and underwent extended
panel testing for RAD51C, RAD51D and BRIP1 along-with somatic testing. Overall, we
found a 97.7% uptake of parallel multi-gene germline and somatic testing via the cancer
MDT mediated mainstreaming pathway.
All of the patients were counselled and consented by a member of the cancer MDT,
with 45% (n = 137) by a medical oncology member, 36% (n = 110) by a surgical oncology
member and 18% (n = 56) by a CNS. The majority required a single pre-test consultation
(78%) prior to consenting, whereas 18% (n = 54) required two consultations, 4% (n = 13)
required three and one patient required four consultations prior to decision to undergo
testing (Table 1). The number of pre-test counselling sessions needed varied significantly
depending on the clinical professional undertaking counselling. Counselling by CNS
was more frequently associated with needing more than one consultation (53.6% (30/56))
compared to counselling by a medical oncologist (15.0% (21/137)) or a surgical gynae-
oncologist (15% (17/110)) (p < 0.001). The number of consultations required did not
significantly differ whether (a) the patient was newly diagnosed or under follow up; and
(b) if they were undergoing active treatment or not (Table 1).
Table 1. Factors associated with number of pre-test consultations.
Variation 1 Consultationn (%)
>1 Consultation
n (%) p-Value *
Member of oncology team undertaking pre-test counselling
Medical Oncologist 116/235 (49%) 21/68 (30%) <0.001
Surgical Oncologist 93/235 (40%) 17/68 (22%)
Clinical nurse specialist 26/235 (12%) 30/68 (48%)
Disease status at the time of counselling
New diagnosis of ovarian
cancer 127/235 (54%) 40/68 (59%) 0.580
Under follow up 108/235 (46%) 28/68 (41%)
Treatment status at the time of counselling
Undergoing treatment 155/235 (66%) 50/68 (74%) 0.303
Not on treatment 80/235 (34%) 18/68 (26%)
* Chi-square test comparing ‘1 consultation and >1 consultation groups’ by variables of type of counselling
clinician, disease status and treatment status at time of pre-test counselling.
Patient demographics and clinical characteristics are summarised in Table 2. The
median age at OC diagnosis was 54 years (IQR 51–62) in germline PV compared with 61
(IQR 51–71) in BRCA wild type (BRCA-WT) (p = 0.001) patients. In germline BRCA1/BRCA2/
RAD51C/RAD51D/BRIP1 PVs, 44.4% (24/54) had a positive FH compared to 11.3% (28/249)
of sporadic tumours (p < 0.001) (Table 2). Thus 55.6% of PVs would have been missed by
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using FH alone. Only 2/7 of RAD51C/RAD51D/BRIP1 PVs had a positive FH. Ethnicity of
OC cases included 196 (64.7%) White, 28 (9.2%) Black, 52 (17.2%) South Asian and 27 (8.9%)
were classed as ‘other’. In women with somatic BRCA1/BRCA2 PV, the median age at
diagnosis was 61 (IQR 59–66) and 13% (2/15) had a positive FH. Most PVs had a high-
grade serous (HGS) histology except one BRCA1 with grade 3 endometrioid carcinoma
and one BRIP1 with mixed epithelial adenocarcinoma. There was no significant difference
in distribution of PVs by ethnicity, stage at diagnosis, timing of surgery or resection status
(Table 2). In post-chemotherapy cytoreductive surgery specimens, chemotherapy response
score (CRS) of 3 (minimal residual disease) was recorded in 13/69 (18.8%) germline and
somatic PVs compared to 13/234 (5.6%) of BRCA-WT tumours (p = 0.025).
Table 2. Demographic and clinical characteristics NELCN cohort.
Category No Germline Pathogenic Variants Germline Pathogenic Variants Significance
Total 249/303 (82.2%) 54/303 (17.8%)
Ethnicity
White 164/249 (65.9%) 32/54 (59.3%)
p = 0.515
Black 23/249 (9.2%) 5/54 (9.3%)
South Asian 39/249 (15.7%) 13/54 (24.1%)
Other 23/249 (9.2%) 4/54 (7.4%)
Age in years
Median (IQR) 61 (51–71) 54 (51–62) p < 0.001
Family History
Positive 28/249 (11.2%) 24/54 (44.4%)
p < 0.001
Negative 221/249 (88.8%) 30/54 (55.6%)
Histology
HGSC 207/249 (83.1%) 52/54 (96.3%)
p = 0.010
All others 42/249 (16.9%) 2/52 (3.7%)
Stage
Early stage 57/249 (22.9%) 10/54 (18.5%)
p = 0.589
Advanced stage 192/ 249 (77.1%) 44/54 (81.5%)
No Pathogenic Variants Total Germline or Somatic PathogenicVariants (PV) Germline PV Somatic PV
Total 234/303 (77.2%) 69/303 (22.8%) * 54/303 (17.8%) 15/232 (6.5%) *
Timing of surgery
Primary surgery 115/234 (49.1%) 30/69 (43.5%) 23/54 (42.6%) 7/15 (46.7%)
Interval surgery 69/234 (29.5%) 28/69 (40.6%) 23/54 (42.6%) 5/15 (33.3%)
Delayed surgery 12/234 (5.1%) 4/69 (5.8%) 2/54 (3.7%) 2/15 (13.3%)
no surgery 38/234 (16.1%) 7/69 (10.1%) 1/54 (1.9%) 1/15 (6.7%)
significance p = 0.307
Disease status of ovarian cancer at time of counselling
New diagnosis 126/234 (53.8%) 41/69 (59.4%) 35/54 (64.8%) 6/15 (40%)
Under follow up 108/234 (46.2%) 28/69 (40.6%) 19/54 (35.2%) 9/15 (60%)
significance p = 0.463
Chemotherapy response score
1 4/234 (1.7%) 0 0 0
2 52/234 (22.2%) 13/69 (18.8%) 12/54 (22.2%) 1/15 (6.7%)
3 13/234 (5.6%) 13/69 (18.8%) 9/54 (16.7%) 4/15 (26.7%)
Not applicable 165/234 (70.5%) 43/69 (60.0%) 33/54 (61.1%) 10/15 (66.7)
significance p = 0.025
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Table 2. Cont.
Category No Germline Pathogenic Variants Germline Pathogenic Variants Significance
Resection (residual disease) status post surgery
R0 175/234 (74.8%) 54/69 (78.2%) 42/54 (77.8%) 12/15 (80%)
R1 14/234 (6.0%) 4/69 (5.8%) 3/54 (5.6%) 1/15 (6.7%)
R2 7/234 (3.0%) 5/69 (7.2%) 3/54 (5.6%) 2/15 (13.3%)
Not applicable 38/234 (16.2%) 6/69 (8.7%) 6/54 (11.1%) 0/15 (0%)
significance p = 0.276
Mutation Prevalence NELCN Cohort
Gene n Pathogenic (%) VUS (%)
NELCN cohort
Germline
BRCA1 303 33 (11%) 3 (1.0%)
BRCA2 303 14 (4.6%) 7 (2.3%)
RAD51C 303 2 (0.7%) 2 (0.7%)
RAD51D 303 3 (1.0%) 2 (0.7%)
BRIP1 303 2 (0.7%) 6 (2.0%)
Total Germline PVs 303 54 (17.8%) 20 (6.6%)
Sequence PVs 54 48 (88.9%) -
LGR PVs 54 6 (11.1%) -
Somatic
BRCA1 232 11 (3.6%) 1 (3%)
BRCA2 232 4 (1.3%) 4 (1.3%)
Total Somatic PVs 232 15 (6.6%) 5 (2.2%)
Total PVs 303 69 (22.8%) 25 (8.3%)
Pathogenic variants = class 4/5 variant in BRCA1, BRCA2, RAD51C, RAD51D, BRIP1. Family history positive = first-degree or second
degree relative with ovary and/or breast cancer. HGSC = high grade serous carcinoma. Early stage = stage 1–2; advanced stage = stage 3–4.
R0 = zero or nil residual disease, R1 = ≤1 cm residual disease, R2 = >1 cm residual disease. IQR = inter quartile range, PV = Pathogenic
variants, VUS = Variants of uncertain significance, LGR- large genomic rearrangements. This table describes outcomes by two groups:
(a) with and (b) without germline/somatic pathogenic variants. Two-sided p-values were reported for statistical tests comparing these two
groups * Results of somatic testing at time of analysis for 71 patients were unavailable (only 232 patients had paired samples). Of these
71 patients 9 had a germline PV.
Validation of 3 mm FFPE punch biopsies for somatic testing:
Analysis of 3 mm Keyes punch biopsy and 5 × 5 µM unstained sections from the same
FFPE tumour block demonstrated comparable DNA concentration and yield; therefore,
archived tumour samples of patients under follow-up were processed as 3 mm core which
proved time-efficient, as it reduced consultant pathologist time needed for review, retrieval
and marking of slides. This is therefore likely to be more cost-efficient (Table 3).
Table 3. Comparison of DNA concentration and yield from FFPE 3 mm core and unstained sections
of tumour tissue.
Case ID
DNA Concentration (ng/µL) DNA Yield (µg)
Slides Punch Slides Punch
Case 1 69.35 176.4 6.94 17.64
Case 2 40.16 60.49 4.02 6.05
Case 3 25.12 69.64 2.51 6.96
Case 4 45.19 115.9 4.52 11.59
Case 5 54.02 41.93 5.40 4.19
Table 3 describes the validation data of DNA yield from FFPE 3 mm core biopsies and unstained sections of
tumour tissue.
Tumour testing results were available for 232 NELCN cases. Of the 71 cases without
tumour testing results, 40 cases lacked available archived tumour tissue for analysis (unable
to retrieve from pathology archive or surgery at another cancer centre); and 25 archived
cases lacked any tissue with adequate neoplastic content (minimal diagnostic biopsy
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or post-chemotherapy tumour necrosis leaving no viable sample for analysis); and six
test results were awaited at the time of analysis (delays due to COVID pandemic). Of
these 71 cases without a somatic result, nine had a PV on germline genetic testing (four
BRCA1, three BRCA2, one RAD51C, one RAD51D). Of the 232 NELCN tumour samples
that underwent testing, 19 (8.9%) failed analysis due to fragmented DNA or low neoplastic
content. Of these failed 19 cases, one had a BRCA1 PV and one a RAD51D PV on germline
testing. Further details on tumour tissue processing are provided in Table 4. The failure
rate was higher for diagnostic biopsies (22.9%; 11/48) compared to primary cytoreductive
surgical specimens (5.4%; 6/110) and post-chemotherapy surgical specimens (2.7%; 2/74).
Primary-surgery specimens that failed analysis were due to fragmented DNA. There were
11 (out of 232) samples categorised with <20% neoplastic content, of which five (45%) were
subsequently found to be adequate for analysis (Table 4). A majority of the samples were
sent for analysis as 3 mm core biopsies from paraffin blocks (174/232, 75%) and the rest as
unstained slides (58/232, 25%). Failure rates were 3/174 (1.7%) in 3 mm cores and 16/58
(27.6%) in unstained slides, respectively. However, 6/16 failed analysis in the unstained
slides group had <20% neoplastic content. In our centre, tissue was preferentially sent
as unstained slides if neoplastic content was <20% or the sample was a small volume
diagnostic biopsy.
Table 4. NELCN tumour tissue BRCA1/BRCA2 next generation sequencing analysis.
Category Successfully Reported (n,%) Failed Analysis (n,%)
Total number of samples 213/232 (91.8%) 19/232 (8.9%) *
Type of tissue
Pre-chemo diagnostic biopsy 37/48 (77.1%) 11/48 (22.9%)
Primary surgery 104/110 (94.5%) 6/110 (5.5%)
Post-chemo cytoreductive
surgery 72/74 (97.3%) 2/74 (2.7%)
Type of tumour sample
3 mm core from FFPE 171/174 (98.3%) 3/174 (1.7%)
5 × 5 µM unstained slides 42/58 (72.4%) 16/58 (27.6%)
Neoplastic content
<20% 5/11 (45.5%) 6/11 (54.5%)
20–50% 33/40 (82.5%) 7/40 (17.5%)
>50% 175/181 (96.7%) 6/181 (3.4%)
This table describes the results of BRCA testing of tumour tissue in the NELCN cohort. Results are available for
232 cases. * Of the 19 failed analysis, one had a BRCA1 PV and one a RAD51D PV.
Genetic testing results:
Following multi-gene germline testing, 54 germline PVs were identified in 303 women
from the NELCN cohort (Supplementary Table S1). Of these PVs, 33 (11%) were BRCA1;
14 (4.6%) BRCA2, 2 (0.7%) RAD51C, 3 (1.0%) RAD51D and 2 (0.7%) BRIP1). Six PVs were
large genomic rearrangements (LGR) and detected by MLPA: four in BRCA1, one in BRCA2
and one in RAD51C. The germline VUS rate in BRCA1/BRCA2 was 3.3% (n = 10) and 3.3%
(n = 10) in RAD51C/RAD51D and BRIP1 (Table 5). Germline BRCA1/BRCA2 testing in the
Manchester cases identified 11 (9.5%) PVs, of which 8 (6.9%) were BRCA1 and 3 (2.6%) were
BRCA2 PVs (Supplementary Table S1). Additionally, one BRCA1 VUS was identified. The
median age of the Manchester cohort was 63 years (IQR = 55–72). Overall, 14 Manchester
patients had a strong FH of cancer. Four of the eleven germline PV had a strong FH,
while seven lacked a strong FH and would have been missed without unselected testing.
Combining data from NELCN and Manchester series, the total BRCA1/BRCA2 germline
PV rate was 15.5% (65/419) and BRCA1/BRCA2 germline VUS rate was 2.6% (11/419).
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Table 5. Mutation Prevalence (Manchester cohort).
Gene n Pathogenic (%) VUS (%)
Manchester Cohort
Germline
BRCA1 116 8 (6.9%) 1 (0.9%)
BRCA2 116 3 (2.6%)
Total Germline PVs 11 (9.5%)
Sequence PVs 11 10 (90.9%)
LGR PVs 11 1 (9.1%)
Somatic
BRCA1 116 7 (6%) 1 (0.9%)
BRCA2 116 5 (4.3%) 1 (0.9%)
Total Somatic PVs 12 (10.3%) 2 (1.8%)
Total PVs 116 23 (19.8%)
This table describes the prevalence of variants in the Manchester cohort. VUS—variants of uncertain significance.
PV—pathogenic variants. LGR—Large genomic rearrangements.
A total of 232 tumour BRCA1/BRCA2 results were available at the time of analysis
from NELCN cases. Somatic BRCA1/BRCA2 PVs were detected in 15 (6.6%) cases and
the VUS rate was 2.2% (n = 5). Tumour BRCA1/BRCA2 testing in 116 Manchester cases
identified 7 (6%) BRCA1 and 5 (4.3%) BRCA2 somatic PVs as well as 1 (0.9%) BRCA1 and
1 (0.9%) BRCA2 somatic VUS each (Table 5). The total BRCA1/BRCA2 somatic PV rate
was 7.8% (27/348) and somatic VUS rate was 2% (7/348). A germline or somatic PV was
identified in 22% (92/419) patients overall. The list of all the variants identified are detailed
in Supplementary Table S1. PARP-i treatment was commenced in 49 (16%) NELCN women
(27 following primary treatment and 22 following recurrence).
BRCA1/BRCA2 germline and somatic PV concordance:
Concordance of BRCA1/BRCA2 PV identified through germline and tumour testing
was explored. This included 232 paired samples with results from NELCN and 116 paired
samples with results from Manchester NHS Trust. There were six BRCA1/BRCA2 PVs that
showed discordance between germline and tumour testing, five in the NELCN cases and
one from the Manchester cases, comprising 10.3% of all germline PVs. Five of these six
BRCA1/BRCA2 PVs were LGR that were not detected on somatic testing; one (3%) germline
mutation (from NELCN cases) was initially reported in the somatic report but not in the
germline. This mutation was then subsequently identified in the germline following re-
analysis of the germline sample. The inability of routine somatic testing to reliably identify
LGRs is an important finding with implications for those developing and/or implementing
OC mainstreaming pathways and for those whose pathways currently use a somatic testing
first triage mechanism. It is critical that patients with LGRs are not missed both from a
cancer treatment perspective as well as for precision prevention in unaffected relatives
with a PV identified through cascade testing.
Pathway improvements:
Changes to the NELCN pathway were incorporated over time to improve logistic
efficiencies, communication between team members and timely communication of result to
the patient. These included: agreement on a standardised format for reports received from
genomic laboratories and omitting of reporting class-1 and class-2 variants. This improved
interpretability by cancer clinicians and reduced unnecessary distress in patients.
Initially somatic reports were uploaded as supplementary reports to the original
histology result but this caused delays in clinician receiving the information and commu-
nicating this to the patient. This was addressed by results being directly sent from the
genomic laboratory creating to a shared email-box which was accessed by all members of
the clinical team. Responsibility for monitoring and ensuring all results were actioned was
subsequently undertaken by the lead medical oncologist.
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Electronic communication with electronic request forms being sent directly to cellular
pathology lead scientist rather than to the lead histopathologist, triggered the laboratory
technician to pull the relevant blocks and slides for the attention of the gynaecological
histopathologist, minimising the delay between clinician request and sample being sent to
the genomic laboratory.
The NELCN has a Bengali speaking ethnic minority population, which varies from
3% to 33% depending on the borough. All patient facing documents were translated into
Bengali to improve engagement and communication with Bengali patients and family
members as well as improve decision making. Additionally, a Bengali-speaking clinical
member of the extended team, acted as an advocate during genetic counselling.
4. Discussion
We demonstrate that unselected concomitant/parallel panel germline and somatic
testing at OC diagnosis can be implemented within the NHS setting, and delivered by
treating cancer clinicians/professionals through a cancer-MDT coordinated approach. Pre-
test counselling was undertaken by all members of the cancer MDT team including medical
oncologists, surgical oncologists and CNSs. Consistent with other reports of high uptake
rates for BRCA testing [23,32–34], we showed this high acceptability extends to panel
germline and somatic genetic testing too, with an uptake rate of 97%. PV carriers were
younger, more likely to have a strong FH of cancer, HGSC histology and a CRS of 3 at
histology. PV status was independent ethnicity, stage at diagnosis, timing of surgery or
resection status. We undertook genetic testing prospectively for newly diagnosed patients
and also for patients undergoing follow-up. Restricting this to prospective implementation
of newly diagnosed cases alone (as has been implemented in some centres) would have
missed 19 (19/54, 35.1%) germline PVs which were detected in the follow-up patients, thus
significantly affecting screening/prevention options for these unaffected family members.
A total of 56% of PVs would have been missed by using an FH based approach alone,
reconfirming the importance of unselected testing and a mainstreaming approach. This
is consistent with reports from others who also showed that around 50% PVs lacked a
strong FH of BC or OC [23,33]. The BRCA PV prevalence in our NELCN cohort was
higher than the Manchester cohort. Some boroughs in North East of London are known
to have an Ashkenazi Jewish (AJ) population and the presence of AJ founder mutations
in seven NELCN OC cases (Supplementary Table S1) is a contributory factor towards this
as BRCA PV are commoner in AJ compared to non-AJ general population OC cases [35].
We found seven AJ BRCA founder mutations in the NELCN cohort but none of these
patients self-reported Jewish ethnicity at recruitment. These patients may have had mixed
parentage or grand-parentage and been unaware of their ethnicity or may have preferred
not to report/disclose Jewish ethnicity. Additionally, NELCN includes 122 women who
had previously been diagnosed and were alive at the time of commencement of the study.
Although short term survival for BRCA PV carriers is higher, we did not find the sub-group
of 122 women may be enriched for PV.
Our data show that over 1 in 5 (22%) patients have a PV which can affect their
treatment, and 1 in 6 have a germline PV which can also affect predictive testing and
screening and prevention in unaffected family members. This is consistent with some
other reports in the literature [23,33,36,37]. Testing for a panel which includes RAD51C,
RAD51D, BRIP1 is not currently part of the NHS Genomics test directory and therefore
not mandatory across the UK. However, it can if implemented identify an additional 13%
(7/54) PVs, with a prevalence of 2.3% in OC patients, whose families can benefit from
precision prevention. Rust et al. showed a slight increase in PVs detected with additional
RAD51C/RAD51D testing but this was not completely unselected in their cohort and was
undertaken either sequentially or in those with a strong FH [33]. Our data confirm the
benefit of amending the UK test directory criteria to offer multi-gene panel testing to all UK
women with OC. Our multi-gene germline test includes high- and intermediate risk genes
which have already proven clinical utility [38]. A number of commercially available panels
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are available today which test for many more (30–100) genes. However, it is important
that only genes of established clinical utility are tested for. We are against indiscriminate
panel testing for genes without established clinical utility [39,40]. In addition to RAD51C,
RAD51D and BRIP1 genes, it would be appropriate for an OC panel to also include
PALB2 and Lynch Syndrome genes going forward. PALB2 has recently been reported as a
moderate risk OC gene [41] and Lynch Syndrome (MMR) genes may be found in another
1% OC patients [42–44]. Some initial reports suggest that cascade testing rates may be
lower following mainstreaming compared to testing in clinical genetics [34]. However,
all our patients with PVs are reviewed in clinical genetics teams, who are responsible for
facilitating cascade testing. Additionally, cascade testing rates are likely to increase with
longer follow up.
As multiple genes get incorporated into OC testing panels, the reported VUS rate will
also increase. Our germline panel VUS rate was 6.6% and is comparable to that reported
by others [45,46]. VUS reporting and subsequent management can pose challenges for
counselling, variant monitoring and onwards risk management. This will become an
increasingly important issue with widening of the panel of genes tested for [47]. Risk reduc-
ing surgery, chemoprevention, screening or downstream predictive testing for unaffected
family members, is not recommended in individuals with a VUS. Our report also highlights
the importance of uniform classification and standardised reporting of class 3 variants
(VUS) across genetic laboratories, including the description in clinical reports issued. The
Cancer Variant Interpretation Group UK (CanVIG-UK) now provides an exemplar of a
multidisciplinary network addressing this nationally [30]. This improves interpretability
of reports by cancer clinicians. Appropriate pre-test education of patients and providers
is necessary to limit the harm that could result from VUS misinterpretation. While not
of immediate direct relevance, a proportion of VUS will be reclassified in the future to
PVs and then have implications for the patients and relatives. This reclassification rate
has been reported as around 9% in a large cohort [48]. In our cohort, a germline mutation
BRCA1 c.442-22_442-13del reported in somatic but missed in initial germline (identified in
re-analysis of germline) was initially reported as Class 3 VUS and subsequently a year on
from testing, was re-classified as a PV.
Strengths of this study include prospective design and systematic approach to include
all patients including those on follow up, as well as the high acceptability and uptake
rates demonstrated with our pathway and testing process. The upfront staff training
implemented across the pathway and continued support provided along-with broad
stakeholder engagement contributed to improved patient experience and satisfaction.
The extra efforts undertaken to engage with our ethnic minority Bengali population is
another strength. In order to broaden access and informed decision making we translated
information sheets into local Bengali language and trained a Bangladeshi oncology team
member who was instrumental in engaging them in genetic counselling. Our analysis also
demonstrates likely success rates for tumour testing for different types of samples which
can be helpful for counselling patients and planning services. Limitations include lack
of qualitative data and long term follow up data on patient outcomes. These are being
collected.
Mainstreaming models such as ours delivered by the cancer MDT team enables
implementation of large-scale genetic testing at cancer diagnosis. This approach too
can encompass more than one pre-test counselling session where needed. A total of
22% women needed and received more than one pre-test counselling session in our study.
Most other mainstreaming studies do not report on the number of pre-test counselling
sessions needed or if multiple were offered. Our clinical nurse specialists favoured utilising
more appointments/consultations prior to recruitment. While we did not undertake a
formal quantitative assessment of reasons for multiple consultations, colleague feedback
indicates these included, some patients needing more time to assimilate information and
reflect on it before deciding and/or the need to discuss further with family before decision
making; as well as a clinical assessment of not overloading the patient with too much
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information at the first setting especially if they were struggling with managing decision
making and information related to their cancer care at the appointment. The issues of some
initially long consultations and time pressures in a busy oncology clinic also contributed to
this. Other examples of models used to deliver unselected genetic testing at OC diagnosis
include a genetics team embedded in oncology clinics, [25] genetic nurse coordinated
model [24] and medical oncology [32] delivered testing.
Validation and implementation of 3 mm cored biopsies from FFPE tumour blocks en-
abled time- and resource-efficient processing of archived samples. This is particularly suited
for archived FFPE tissue (analysis of retrospective cases) and gave a comparable/higher
DNA yield than that obtained through slides. Although, we were unable to test 21% of
archived tumour samples, undertaking tumour testing at time of diagnosis for future cases
will overcome this. Our pathway now incorporates pathology processing/preparation
for genetic testing for all cases at the time of routine histopathology analysis of the ini-
tial diagnostic or surgical specimen itself. As a large proportion of failed analysis was
pre-treatment diagnostic biopsies, we now routinely obtain additional tissue cores for all
women suspected of advanced ovarian malignancy at the time of their diagnostic biopsy.
This minimises additional pathology laboratory resources needed and is more cost and
time efficient. We also provide estimates of failure rates of diagnostic biopsy (~23%),
which is relevant for counselling and management of patients planned for neo-adjuvant
chemotherapy. NHS Laboratory guidelines suggest the minimum tumour content for NGS
somatic/tumour testing referrals should be 20% [13]. However, we showed benefit of
undertaking tumour testing even with <20% content in 45% of such cases. Hence, tumour
testing should not be held back in cases with low tumour content as it could be successful in
almost half these cases, thus identifying additional women who may benefit from PARP-i
treatment.
There has been debate whether both germline and somatic testing should be offered
to all; whether unselected germline testing should be offered as first line, followed by
somatic testing if germline is negative for PV; or whether reflex somatic testing should be
done first, reserving germline if a somatic PV is identified. PVs caused by large genomic
rearrangements (LGRs) are missed when PCR-based testing alone is used [49,50]. MLPA is
a commonly/routinely used technique to detect LGRs and is found to be highly sensitive
and inexpensive [51,52]. LGRs are far more prevalent in BRCA1 than BRCA2 genes and
have been reported to account for a wide range of BRCA1 (up to 27%) and BRCA2 (up
to 11%) PVs [53–55]. In a large study, LGRs were reported to constitute around 24% of
BRCA1/BRCA2 PVs in high-risk breast/ovarian cancer families, [55] while lower rates are re-
ported in other series and in individuals without strong family histories [53,55,56]. Reports
suggest significant ethnic variation in the presence of LGR-related PVs: [55] African (2.4%),
Caribbean and Latin American (6.7%), Danish (9.2%) and Spanish ancestry (14.5%) [55–57].
A disadvantage of using an initial tumour/somatic testing triage strategy is the possibil-
ity of missing LGRs. The 11% LGR-rate in our cohort (6/54) is similar to the LGR rate
reported in some high-risk breast and ovarian cancer families [54]. In the majority of
diagnostic laboratories, NGS tumour/somatic BRCA-testing is not validated for detection
of LGRs [50]. While sequential tumour/somatic followed by germline testing may be a less
costly approach [58], this strategy runs the risk of missing some germline PVs, particularly
LGRs. This can have significant consequences for cancer prevention in families which are
missed. Additionally, although reflex tumour testing can identify PVs seen in the germline,
up to 31% of patients found to have a PV in the tumour may not get referred for genetic
counselling or germline testing [59]. This highlights a potential limitation of a somatic
first strategy, and the need for more robust implementation pathways with built in quality
control and fail-safe mechanisms.
In contrast to our findings, a few earlier reports suggest 100% concordance between
somatic and germline testing [45,60,61]. However, the proportion of LGRs amongst the
BRCA mutations reported in these studies is unknown, as these have not been described. It
is probable/likely that these studies did not have any LGRs in their mutation spectrum. In
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our cohort, somatic BRCA-testing alone, would have missed 9.2% (4/54) of BRCA1/BRCA2
germline PVs and seven PVs in RAD51C/RAD51D and BRIP1, which comprise 20% (11/54)
of germline PVs detected from 5-gene panel testing, who can benefit from targeted therapy
and downstream predictive testing.
Germline-testing alone would have missed 2% (1/54) germline BRCA1/BRCA2 PVs,
and 15 somatic PVs, comprising 23.1% (16/69) of all BRCA1/BRCA2 PVs in this cohort,
who can benefit from PARP-i treatment. The germline PV missed is an error, which is
unlikely to be repeated. A germline first followed by a somatic testing strategy could be
an alternative option, but this approach will lead to a longer delay in turn-around times
and increase clinician counselling time for giving results as this will need to be done twice.
It is also likely to increase the laboratory processing and reporting time and costs, as this
is undertaken after initial diagnosis (not contemporaneously with diagnostic reporting).
In our experience, a simultaneous or parallel somatic/tumour and germline strategy is a
more efficient approach for patients.
5. Conclusions
We demonstrate successful implementation of unselected 5-panel germline and con-
comitant somatic BRCA1/BRCA2 testing for patients with OC. BRCA1/BRCA2 germline PVs
were identified in 15.5% patients and BRCA1/BRCA2 somatic PVs in 7.8%. RAD51C/RAD51D/
BRIP1 PVs comprised 13% of PVs and were identified in an additional 2.3% patients. A
total of 11% germline PVs are LGRs and are missed by a somatic first testing strategy. A
total of 20% of germline PVs would be missed if somatic BRCA-testing alone was used
to triage for germline testing. A total of 55.6% germline PVs would have been missed by
using FH ascertainment alone. The somatic testing failure rate is higher (23%) for patients
undergoing diagnostic biopsies. Retrospective archival FFPE tissue testing is feasible using
3 mm punch biopsies from tumour blocks. Our findings favour a prospective parallel
somatic and germline panel testing approach as a clinically efficient strategy which max-
imises variant identification for clinical benefit. The UK Genomics test directory criteria
should be expanded to include a panel of OC genes. Formal cost-effectiveness analysis for
panel testing is needed and can facilitate wider clinical implementation.
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